

Genetic overlap between schizophrenia and developmental psychopathology: a longitudinal approach applied to common childhood disorders between age 7 and 15 years

Michel G. Nivard, PhD^{1*}, Suzanne H. Gage, PhD^{2,3}, Jouke J. Hottenga, PhD^{1,4}, Catherina E.M. van Beijsterveldt, PhD¹, Abdel Abdellaoui, PhD¹, Bart M.L. Baselmans, MSc^{1,4}, Lannie Ligthart, PhD^{1,4}, Beate St Pourcain,^{2,5} Dorret I. Boomsma, PhD^{1,4,6}, Marcus R. Munafò, PhD^{2,3} & Christel M. Middeldorp, PhD MD^{1,6,7}

1. Biological Psychology, VU University, Amsterdam, The Netherlands
2. MRC Integrative Epidemiology Unit at the University of Bristol, UK
3. UK Centre for Tobacco and Alcohol Studies, School of Experimental Psychology, University of Bristol, Bristol, UK
4. EMGO Institute for Health and Care Research (EMGO+), VU University Medical Center, Amsterdam, The Netherlands
5. Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands,
6. Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands
7. Department of Child and Adolescent Psychiatry, GGZ inGeest / VU University Medical Centre, Amsterdam, The Netherlands

*: Correspondence should be addressed to Michel G Nivard m.g.nivard@vu.nl

Van der Boechorstraat 1081 BT Amsterdam, The Netherlands.

Author contributions:

MGN & CMM devised the study design

CMM, MRM & DIB supervised the research

MGN, SHG performed the analysis

MGN, CMM, DIB, MRM, SHG wrote the manuscript

AA, BSP, CEMB, JJH, BMLB, LL contributed to the analyses, genotypes and phenotypes.

Abstract

Various non-psychotic psychiatric disorders in childhood and adolescence can precede the onset of schizophrenia, but the nature of this relationship remains unclear. We investigated to what extent the association between schizophrenia and psychiatric disorders in childhood is explained by shared genetic risk factors.

Polygenic risk scores (PRS), reflecting an individual's genetic risk for schizophrenia, were constructed for participants in two birth cohorts (2,588 children from the Netherlands Twin Register (NTR) and 6,127 from the Avon Longitudinal Study of Parents And Children (ALSPAC)). The associations between schizophrenia PRS and measures of anxiety, depression, attention deficit hyperactivity disorder (ADHD), and oppositional defiant disorder/conduct disorder (ODD/CD) were estimated at age 7, 10, 12/13 and 15 years in the two cohorts. Results were then meta-analyzed, and age-effects and differences in the associations between disorders and PRS were formally tested in a meta-regression.

The schizophrenia PRS was associated with childhood and adolescent psychopathology. Where the association was weaker for ODD/CD at age 7. The associations increased with age this increase was steepest for ADHD and ODD/CD. The results are consistent with a common genetic etiology of schizophrenia and developmental psychopathology as well as with a stronger shared genetic etiology between schizophrenia and adolescent onset psychopathology.

A multivariate meta-analysis of multiple and repeated observations enabled to optimally use the longitudinal data across diagnoses in order to provide knowledge on how childhood disorders develop into severe adult psychiatric disorders.

Introduction

The onset of schizophrenia generally occurs during adolescence or early adulthood¹, but it is well established that non-psychotic psychiatric symptoms can be present in the period before the first psychotic episode. The prodromal phase is characterized by neurodevelopmental deficits,²⁻⁴ cognitive learning and memory problems,⁵ and elevated psychiatric symptoms.⁶ Well before the prodromal phase, psychiatric symptoms or disorders are more prevalent in individuals who later develop schizophrenia, as becomes apparent from longitudinal population based cohorts,^{7,8} retrospective assessments of schizophrenia cases,⁹ and from studies on populations at risk for developing schizophrenia.¹⁰ Both externalizing symptoms or disorders, including attention deficit hyperactivity disorder, conduct disorder, aggression, and anti-social behavior,^{11,12} and internalizing symptoms or disorders, including anxiety and depression, are associated with a higher risk of schizophrenia.^{7,8,11,13-16} In sum, these studies indicate that the onset of schizophrenia can be preceded by a broad range of childhood and adolescent psychopathology.

The early detection of schizophrenia can improve outcomes,⁸ and preventive treatment for individuals at risk for schizophrenia can reduce the risk of psychosis.^{17,18} Insight into the risk factors associated with the predictors of schizophrenia may facilitate early detection. Here, we focused on the role of genetic risk factors. Schizophrenia is highly heritability (approximately 80%¹⁹) and molecular genetic and twin and family studies generally found evidence for a genetic association between childhood and adult psychopathologies,²⁰⁻²⁷ with one exception.²⁸ Consequently, we hypothesized that genetic risk factors for schizophrenia are associated with childhood and adolescent psychopathology. We further expected this association to become stronger from childhood into adolescence, since the prevalence rates of prodromal symptoms and of psychiatric disorders genetically correlated to schizophrenia (i.e., major depression and bipolar disorder) show a marked increase during adolescence.¹

We tested these hypotheses with a novel approach which combines the results of multiple polygenic risk score (PRS) analyses of the genetic associations between schizophrenia and longitudinal

psychopathology measures into a single multivariate meta-analysis. The PRS were based on the most recent schizophrenia GWA meta-analysis²⁹ that yielded 108 genome wide associations, which provides an excellent starting point to investigate the genetic overlap between schizophrenia and other traits (for a review of PRS analyses see³⁰⁻³²). Predictions were tested in two large cohorts with DSM-IV³³ based measures of anxiety, depression, attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder and conduct disorder (ODD/CD) assessed at ages 7, 10, 12/13 and 15 years. To simultaneously consider the 192 univariate PRS analyses, a multivariate meta-regression was performed while accounting for the correlations between the multiple polygenic scores and between the psychopathology measures. The multivariate meta-analysis framework provided the opportunity to test differences in the association between schizophrenia PRS and childhood psychopathology between cohorts, disorders and over age.

Methods

Subjects

The Netherlands Twin Register (NTR) (www.tweelingenregister.org) follows newborn and adult twins.

In the Young NTR (YNTR), twins are registered by their parents and followed from birth onwards.

Until age 12, parents complete surveys to report on their twins. From age 14 onwards, information is collected by means of self-report.³⁴ In the current study, maternal ratings of childhood

psychopathology collected at age 7, 10, and 12 years were analyzed as well as self-report data

collected between ages 14-16 years. The number of genotyped children with scores available varied

between 1,223 and 2,588 depending on age group (**Supplementary Table 1**). Informed consent was

obtained from all participants. The study was approved by the Central Ethics Committee on Research

Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review

Board certified by the U.S. Office of Human Research Protections (IRB number IRB-2991 under

Federal-wide Assurance-3703; IRB/institute codes, NTR 03-180).

The Avon Longitudinal Study of Parents And Children (ALSPAC) (www.bristol.ac.uk/alspac/) consists

of mothers and their children, born between 1990 and 1991 in the Avon area in southwest England,

UK.³⁵ The ALSPAC cohort includes maternal ratings of psychopathology at age 7, 10, 13, and 15 and

self-ratings at 15 years. The number of genotyped children at each age group varied between 4445

and 6127 (**Supplementary Table 1**). Ethical approval for the study was obtained from the ALSPAC

Ethics and Law Committee and the Local Research Ethics Committees. The study website contains

details of all data available through a fully searchable data dictionary

(www.bris.ac.uk/alspac/researchers/data-access/data-dictionary).

Measures

In the NTR, psychopathology was measured with DSM-IV based symptom scales³⁶ of the age appropriate versions of the Achenbach System of Empirically Based Assessment (ASEBA). For ages 7 to 12, maternal Child Behavior Checklist (CBCL) ratings of the anxiety disorder scale (anxiety), the affective disorder scale (depression), the attention deficit hyperactivity disorder scale (ADHD), and a combined oppositional deviant disorder and conduct disorder ((ODD/CD) scale were analyzed. From age 14 onwards, self-ratings of these scales were analyzed.

In ALSPAC, psychopathology was assessed using the development and wellbeing assessment (DAWBA), which measures the presence of symptoms required for a DSM-IV diagnosis.³⁷ Disorders comparable to the ASEBA scales were included in the analyses: any anxiety disorder (anxiety), major depression (depression), attention deficit hyperactivity disorder (ADHD), and combined oppositional deviant disorder and conduct disorder (ODD/CD).³⁸ Any anxiety disorder included generalized anxiety disorder, specific phobia, social phobia (at age 7, 10, 13, and 15), separation anxiety disorder (at age 7, 10, and 13), and panic disorder and agoraphobia (at age 15). At ages 7, 10, and 13 all ratings were maternal ratings. At age 15, ADHD and CD/ODD were rated by mothers, and anxiety and depression were self-ratings. The DAWBA yields a diagnosis, but also a more finely grained indicator of disease risk, the DAWBA band. DAWBA band scores, which range from 0 to 5, correspond to probabilities of <0.01%, 0.5%, 3%, 15%, 50%, and >70% of satisfying DSM-IV diagnostic criteria.

Genotyping

Genotyping and genotype quality control were performed in accordance with common standards to (for a detailed description see **Supplementary Note 1**).

Polygenic risk scores

Polygenic risk scores (PRS) were calculated by summing the number of risk alleles across all genetic loci (coded as 0,1,2), weighted by the schizophrenia risk conferred by each locus. The risk conferred by each locus was based on the results from the most recent genome-wide association meta-analysis

for schizophrenia (PGC-SCZ2, available online: <http://www.med.unc.edu/pgc/downloads>).²⁹ For all participants, we calculated PRS using LDpred,³⁹ a method which accounts for correlations between adjacent genetic loci, and adjusts the risk conferred by each locus accordingly. LDpred further uses a prior expectation for the per locus risk, which is based on the expected degree of polygenicity in a trait. We computed 6 PRS at 6 different priors for the proportion of SNPs with a casual effect (0.01, 0.05, 0.1, 0.25, 0.5, 1). The discovery markers were not pruned and neither were markers a priori eliminated based on thresholds, instead the effect of all markers, the LD between markers and the prior expectation on the degree of polygenicity were leveraged to obtain updated weights for all markers. For each prior an updated set of weights was obtained, which were converted in a polygenic score for each subject. The inclusion criteria for SNPs were minor allele frequency above 5% and high imputation quality ($R^2 > .9$). The PRS were scaled to unit variance and mean centered within cohort.

Statistical analyses

In NTR and in ALSPAC, 96 (4 age bins x 4 disorders x 6 polygenic scores) regression analyses were performed to analyze the prediction of the psychopathology measures by the schizophrenia PRS. Psychopathology measures were scaled to unit variance. As the NTR contained related individuals, the linear regression was performed using a generalized estimation equation with exchangeable background correlations within family, and robust standard errors. This procedure adequately corrects for the presence of related individuals in the sample.⁴⁰ In the ALSPAC sample, an ordered logistic regression was performed since the DAWBA bands are ordered categorical variables. The ordered logistic regression in ALSPAC was transformed to a scale where the underlying latent variable has variance 1. This results in comparable beta's in the two cohorts, as in both samples an 1 SD increase in the schizophrenia PRS results in an 1 SD increase in the (latent) phenotype, enabling a meta-analysis of regression coefficients from the 96 NTR and 96 ALSPAC analyses. Meta analyses were performed in the metaphor R-package.⁴¹ In contrast to most meta-analyses, the outcome

variables were correlated since within the NTR and ALSPAC the same individuals were repeatedly assessed. The polygenic risk scores are also correlated since they are based on a common set of effect sizes, and only differ in the degree of polygenicity assumed in their construction. These correlations result in dependencies between the parameters to be meta-analyzed. We accounted for this in the meta-analysis by specifying the error covariance matrix as the observed correlations between traits and PRS (see **Supplementary Note 1** for type 1 error simulation and sensitivity analysis).

In the meta-analysis, we tested whether the effect sizes obtained from the 192 univariate PRS analyses departed from zero. We subsequently investigated which variables predicted the strength of the association between psychopathology and schizophrenia PRS in our meta-analysis. In the meta-regression, “age at measurement”, “prior proportion of causal SNPs assumed for PRS”, “cohort” and “disorder” were included as predictors of the strength of the association. Cohort was coded 1 for ALSPAC and 0 for NTR. Age was coded in years over seven (age seven was coded as zero). We considered 4 meta-regression models, including an increasing number of predictors (see Table 1). The most comprehensive model included cohort, age, prior, prior², disorder, ageXdisorder, age², age²Xdisorder. To guard against over fitting, which is a risk in meta-regression,⁴² we performed 1,000 parametric resamples of the data and performed the model selection on each resample (see **Supplementary Note 1**). We report the proportion of resamples in which each model is selected based on the AIC. We further perform two additional mixed effects meta analyses (see **Supplemental Note 1**)

The regression coefficients obtained in polygenic risk score analyses can be translated to genetic correlations between traits.⁴³ We calculated the genetic correlations between schizophrenia and childhood psychopathology based on the best fitting meta-regression model. Since this transformation relies on assumptions regarding the variance explained by the SNPs and the number

of independent SNPs influencing the disorders, we also present the results of the calculations while making different assumptions on the variance explained by all SNPs.

Results

The descriptives of the psychopathology measures revealed the expected sex differences of adolescent girls scoring on internalizing disorders than boys and boys scoring generally higher than girls on ADHD and ODD/CD (**Supplementary Table 1-2 & Supplementary Note 1**). Consequently, sex was included as a covariate in the PRS analyses.

Model fit statistics, and comparative model fit statistics for the four meta-analytic models are presented in **Table 1**. The model in which the association between childhood psychopathology and schizophrenia PRS are predicted by age, prior, prior², disorder and age x disorder (i.e., a different relationship between disorder and schizophrenia PRS over age) outperforms the basic model which only allows for differences in effect sizes between cohorts. Inclusion of non-linear age effects did not yield an improvement in fit. Likelihood-ratio testing and AIC suggested that Model 3 provided the best balance between parsimony and model complexity. In 77.1% of parametric resamples, model 4 provided the best fit to the data according to the AIC, in 99.5% of the resampled datasets either model 3 or 4 provided the best fit. We proceed to interpret the results of model 3 as the increased in complexity in model 4 by the addition of non-linear age effects yields little extra information. Performing additional effects meta regressions did not substantially change the parameter estimates nor the conclusions drawn based on the meta regression (see **Supplemental Note 1**).

In meta-regression model 3, we tested the degree of polygenicity of the association between schizophrenia and childhood psychopathology by varying the covariate values for prior and prior² while keeping the other covariates fixed at their inverse variance weighted means. The prediction accuracy as a function of prior peaked between the prior values of .50 and 1, suggesting the optimal prior can be found in this range (**Supplementary Figure 1**). This result suggests that the relationship between childhood psychopathology and schizophrenia is highly polygenic in nature, i.e., a large

portion of the genome is involved in the relationship between schizophrenia and childhood psychopathology. The forest plot (**Figure 1**), which contains both the empirical and model predicted estimates for the PRS predictions (for PRS prior = 0.50), reveals that the meta-regression predictions are close to the observed PRS regression coefficients.

Figure 2 shows, based on model 3, the associations between schizophrenia PRS and childhood psychopathology as a function of age, and age x disorder, while keeping all other predictors (i.e., cohort, prior and prior²) fixed at their respective inverse variance weighed mean value. The associations increases with age, confirming our hypothesis that the genetic relationship between schizophrenia and developmental psychopathology is stronger in adolescence than in early childhood. The parameter estimates in model 3 (**Table 2**) further indicate that the association with schizophrenia at age 7 was highest for depression (0.0262, Z= 2.227, p < 0.03) and significantly lower for ODD/CD compared to depression (Z=-2.49., p < 0.02). The predictions for ADHD (Z = 1.61, P < 0.11) and anxiety (Z = -.38, p = .70) did not differ with depression. The increase in association with schizophrenia with age was significant for depression (Z = 2.93, p < 0.003) and stronger for ADHD (Z = 4.18, p < 0.001) and ODD/CD (Z = 2.17, p < 0.03) but not anxiety compared to depression (Z = 0.97, p = .30). Further sensitivity analyses showed that the model selection and model parameters were robust to considerable misspecification of the error covariance matrix (see **Supplementary Note 1**).

Finally, based on the relationship between the outcomes of PRS analyses and genetic correlations as described by Dudbridge,⁴³ we computed the expected genetic correlation between developmental psychopathology and schizophrenia as a function of age and split over disorders based on the beta's obtained in the meta-regression (for details see: **Supplementary Note 1**). We assumed that 15% of the variance in childhood psychopathology is captured by the genetic markers used to compute the scores,^{23, 44, 45} that 35% of variance in the schizophrenia liability is explained by the markers included in the score,^{24, 46} and that 200,000 independent genetic effects are captured by the markers included in the PRS. Given these assumptions genetic correlations increase from around 0.10 at age 7 and

around 0.25 at age 16, differences in genetic correlations with schizophrenia between disorders were modest (**Figure 3**). The influence of assuming lower (10%) or higher (20%) true variance explained by all measured genetic markers in childhood psychopathology on the estimated genetic correlation is quantified in **Supplementary Figures 2-3**.

Discussion

We investigated whether associations between schizophrenia PRS and childhood psychopathology were explained by shared genetic risk factors. For childhood and adolescent anxiety, depression, ADHD and OCC/CD we found the association to be significant across all ages. The genetic overlap between schizophrenia PRS and childhood psychopathology became stronger with age. The associations differed between disorders, with e.g. a weaker association for ODD/CD at age 7, and a stronger age related increase for ADHD. Given reasonable assumptions, the observed polygenic risk predictions translate to genetic correlations between schizophrenia and psychopathology increasing from ~ 0.1 in childhood to ~ 0.25 in adolescence. We further found evidence for a high degree of polygenicity in the relationship between schizophrenia PRS and childhood psychopathology, as was evident from the increase in effect with an increase in the polygenicity prior used in computing the polygenic risk scores.

Strengths of our study were the substantial sample sizes of the discovery and target samples. The schizophrenia PRS were based on a large discovery set, a GWAS which revealed 108 genome wide significant loci.²⁹ The target samples varied between 5,354 and 8,253 at different ages, which is substantially higher than the required number of $\sim 2,000$ subjects generally indicated as sufficient for PRS analysis.³⁰ Innovative strengths of our analyses were the explicit modeling of all univariate analysis results in the meta-regression approach which accounted for the covariance between disorders and ages, correction for cohort specific effects and the simultaneous consideration of multiple risk scores trained at different priors.

The use of different measures of psychopathology in ALSPAC and NTR could be considered either a limitation or strength. Both measures were based on maternal and self-ratings that are consistently related to clinical DSM-IV diagnoses.^{36,37,47} As we observed a significant prediction in both cohorts, results can be generalized across different indices of childhood psychopathology. Several genetic studies on ADHD have also shown that genetic factors for clinically diagnosed ADHD overlap with genetic factors influencing continuous ADHD measures in the general population.⁴⁸⁻⁵⁰ These results indicate that combining clinical and population based data in a single study can also be a way to increase sample size and thus statistical power. Another limitation that concerns longitudinal studies is the dropout over the years. We analyzed whether the schizophrenia PRS predicted non-participation and observed significant associations between schizophrenia PRS and non-participation at age 15 in both cohorts and at all ages in ALSPAC (**Supplementary Table 3**). We further observed that non-participation was related to a higher score on psychopathology scales at an earlier age in ALSPAC; this especially holds for externalizing and ADHD at age 13 and 15. In NTR non-participation at age 15 was related to externalizing and depression at age 12 (**Supplementary Table 4**). As those with higher PRS and higher psychopathology scores at earlier ages are more likely to dropout, we expect that the dropout introduces downward bias in the estimated relationship between schizophrenia and childhood psychopathology. Note that only longitudinal analyses can provide insight into the influence of dropout on the estimate genetic relationship between traits, while in univariate studies a failure to participate results in the absence of genetic data and thus the influence of failure to participate cannot be quantified. For more comprehensive genetically informed dropout analysis of the ALSPAC data see:⁵¹.

Previous research focusing on the genetic overlap between schizophrenia and (childhood) psychopathology is largely in line with our results.^{24,25,27,28,52} Three differences are noteworthy. Another study in the ALSPAC sample focused on psychiatric symptoms at age 15 and found that schizophrenia PRS predicted anxiety disorder and negative symptoms, but not depressive disorder and psychotic experiences. The difference with the current results for depression may be explained

by improvements in the method used to compute the polygenic scores and in the definition of the phenotype.²⁷ Two studies by the Psychiatric Genomics Consortium Cross Disorder Group detected strong correlations between major depressive disorder, bipolar disorder and schizophrenia, but no genetic correlation between ADHD and schizophrenia.^{24, 25, 52} The latter is probably explained by the smaller sample size at the time, as is confirmed by recent analyses which detect a significant association between ADHD and schizophrenia.⁵² Finally, a study²⁸ analyzing attention problems and impulsivity, anxiety and a general tendency for psychopathology yielded no significant associations. Yet, the direction of the effects was positive (i.e., higher schizophrenia risk predicted higher scores). As that study comprised polygenic risk scores for 13 traits as well as 50 outcome variables, the multiple-testing burden was considerably higher than in the current study resulting in lower power to detect an effect. Overall, the evidence suggests the presence of a positive genetic correlation between schizophrenia and psychopathology in childhood and in adulthood. Stronger associations are generally reported in adulthood than in childhood. Our findings add a longitudinal and multivariate perspective, and provide evidence for strong polygenicity in the relationship between schizophrenia and childhood psychopathology.

While it is tempting to discuss significant prediction of childhood and adolescent psychopathology by schizophrenia polygenic risk in terms of future clinical risk prediction, we instead offer a word of caution. Genetic prediction is in its infancy. The predictions made, as of yet, are very weak predictors of individual clinical outcomes. The absolute upper bound for genetic risk prediction is easily found by considering the disease concordance for monozygotic, i.e., genetically nearly identical, twins, which is ~50% for schizophrenia. The concordance is a function of shared genetic and environmental exposures both pre and post-natal.^{53, 54} Genetic clinical risk prediction will improve, but will not exceed this upper bound.

The current study shows how longitudinal analysis can provide insight into how genetic factors exert their effects across diagnostic boundaries and over ages. By explicitly testing sources of

heterogeneity (age and disorder) we shed light on the effects of schizophrenia risk genes during childhood. Our findings suggest that there are sets of SNPs broadly influencing psychopathology across ages in the general population, and that there are sets of SNPs of which the effect is either limited puberty or increases in puberty. Our results indicate that age-sensitive genome-wide meta-analysis of repeated measures, in either case-control or population based samples could well identify genetic variants. Some of these genetic variants will increase an individual's vulnerability for psychopathology and may be associated with persistence of symptoms from childhood into adolescence and adulthood, while other variants can be identified that have an age or disorder dependent effect on psychopathology. Identifying not only which variants influence psychopathology but also at what age can aid to focus translational studies on developmental processes.

To conclude, our study shows how genetic risk factors for schizophrenia are of increasing importance during childhood and adolescence and demonstrate the value of longitudinal studies across diagnostic boundaries to increase our insight into the etiology of severe psychiatric disorders.

Acknowledgments.

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This work was supported in part by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_12013/6). This publication is the work of the authors and Michel G. Nivard will serve as guarantor for the contents of this paper. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We are equally grateful to the NTR twins, their parents and other family members who participate in the NTR research. The NTR gratefully acknowledges support from “Genetic influences on stability and change in psychopathology from childhood to young adulthood” (ZonMW 912-10-020) and “Genetics of Mental Illness” (ERC-230374). MGN is supported by Royal Netherlands Academy of Science Professor Award (PAH/6635). The Netherlands Organization for Scientific Research (NWO) and MagW/ZonMW grants Middelgroot-911-09-032, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL, 184.021.007), VU University’s Institute for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam (NCA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health, Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the Avera Institute, Sioux Falls, South Dakota (USA) and the National Institutes of Health (NIH R01 HD042157-01A1, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995).

Conflicts of interest

The authors declare no conflict of interest.

Supplementary information is available at Molecular Psychiatry’s website

Reference List

1. Kessler,R.C., Amminger,G.P., Aguilar-Gaxiola,S., Alonso,J., Lee,S., & Ustun,T.B. Age of onset of mental disorders: a review of recent literature. *Current opinion in psychiatry* 2007; **20**, 359 .
2. Heinrichs,R.W. & Zakzanis,K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology* 1998; **12**, 426 .
3. Kahn,R.S. & Sommer,I.E. The neurobiology and treatment of first-episode schizophrenia. *Molecular psychiatry* 2014.
4. Fusar-Poli,P., Bechdolf,A., Taylor,M.J., Bonoldi,I., Carpenter,W.T., Yung,A.R. *et al.* At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. *Schizophrenia bulletin* 2013; **39**, 923-932 .
5. Woodberry,K.A., Giuliano,A.J., & Seidman,LJ. Premorbid IQ in schizophrenia: a meta-analytic review. *The American journal of psychiatry* 2008; **165**, 579-587 .
6. Cunningham Owens,D.G. & Johnstone,E.C. Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context. *Psychological medicine* 2006; **36**, 1501-1514 .
7. Cannon,M., Caspi,A., Moffitt,T.E., Harrington,H., Taylor,A., Murray,R.M. *et al.* Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. *Archives of general psychiatry* 2002; **59**, 449-456 .
8. Kim-Cohen,J., Caspi,A., Moffitt,T.E., Harrington,H., Milne,B.J., & Poulton,R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. *Archives of general psychiatry* 2003; **60**, 709-717 .
9. Rossi,A., Pollice,R., Daneluzzo,E., Marinangeli,M.G., & Stratta,P. Behavioral neurodevelopment abnormalities and schizophrenic disorder: a retrospective evaluation with the Childhood Behavior Checklist (CBCL). *Schizophrenia research* 2000; **44**, 121-128 .
10. Miller,P.M., Byrne,M., Hodges,A., Lawrie,S.M., & Johnstone,E.C. Childhood behaviour, psychotic symptoms and psychosis onset in young people at high risk of schizophrenia: early findings from the Edinburgh High Risk Study. *Psychological medicine* 2002; **32**, 173-179 .
11. Murtori,F., Salvadori,F., D-Arcangelo,G., Viglione,V., & Picchi,L. Childhood psychopathological antecedents in early onset schizophrenia. *European psychiatry* 2005; **20**, 309-314 .
12. Keshavan,M.S., Diwadkar,V.A., Montrose,D.M., Rajarethinam,R., & Sweeney,J.A. Premorbid indicators and risk for schizophrenia: a selective review and update. *Schizophrenia research* 2005; **79**, 45-57 .

13. Meyer,S.E., Bearden,C.E., Lux,S.R., Gordon,J.L., Johnson,J.K., O'Brien,M.P. *et al.* The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. *Journal of Child & Adolescent Psychopharmacology* 2005; **15**, 434-451 .
14. Fusar-Poli,P., Nelson,B., Valmaggia,L., Yung,A.R., & McGuire,P.K. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. *Schizophrenia bulletin* 2014; **40**, 120-131 .
15. Gajwani,R., Patterson,P., & Birchwood,M. Attachment: Developmental pathways to affective dysregulation in young people at ultra-high risk of developing psychosis. *British Journal of Clinical Psychology* 2013; **52**, 424-437 .
16. Maibing,C.F., Pedersen,C.B.c., Benros,M.E., Mortensen,P.B., Dalsgaard,S.+, & Nordentoft,M. Risk of schizophrenia increases after all child and adolescent psychiatric disorders: a nationwide study. *Schizophrenia bulletin* 2014; sbu119 .
17. Perkins,D.O., Gu,H., Boteva,K., & Lieberman,J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *American Journal of Psychiatry* 2005; **162**, 1785-1804 .
18. Stafford,M.R., Jackson,H., Mayo-Wilson,E., Morrison,A.P., & Kendall,T. Early interventions to prevent psychosis: systematic review and meta-analysis. *Bmj* 2013; **346**, f185 .
19. Sullivan,P.F., Kendler,K.S., & Neale,M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Archives of general psychiatry* 2003; **60**, 1187-1192 .
20. Sanchez-Gistau,V., Romero,S., Moreno,D., de la Serna,E., Baeza,I., Sugranyes,G. *et al.* Psychiatric disorders in child and adolescent offspring of patients with schizophrenia and bipolar disorder: A controlled study. *Schizophrenia research* 2015; **168**, 197-203 .
21. Nivard,M.G., Dolan,C.V., Kendler,K.S., Kan,K.J., Willemsen,G., van Beijsterveldt,C.E. *et al.* Stability in symptoms of anxiety and depression as a function of genotype and environment: a longitudinal twin study from ages 3 to 63 years. *Psychological medicine* 2014; 1-11 .
22. Kan,K.J., Dolan,C.V., Nivard,M.G., Middeldorp,C.M., van Beijsterveldt,C.E., Willemsen,G. *et al.* Genetic and environmental stability in attention problems across the lifespan: evidence from the Netherlands twin register. *Journal of the American Academy of Child & Adolescent Psychiatry* 2013; **52**, 12-25 .
23. Benke,K.S., Nivard,M.G., Velders,F.P., Walters,R.K., Pappa,I., Scheet,P.A. *et al.* A genome-wide association meta-analysis of preschool internalizing problems. *Journal of the American Academy of Child & Adolescent Psychiatry* 2014; **53**, 667-676 .
24. Cross-Disorder Group of the Psychiatric Genomics Consortium Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nature genetics* 2013; **45**, 984-994 .
25. Cross-Disorder Group of the Psychiatric Genomics Consortium Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *The Lancet* 2013; **381**, 1371-1379 .

26. Hamshere, M.L., Stergiakouli, E., Langley, K., Martin, J., Holmans, P., Kent, L. *et al.* Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. *The British Journal of Psychiatry* 2013; **203**, 107-111 .
27. Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M. *et al.* Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. *JAMA Psychiatry*. 2016; **73**.
28. Krapohl, E., Euesden, J., Zabaneh, D., Pingault, J.B., Rimfeld, K., von Stumm, S. *et al.* Phenome-wide analysis of genome-wide polygenic scores. *Molecular psychiatry* 2015.
29. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**, 421-427 .
30. Wray, N.R., Lee, S.H., Mehta, D., Vinkhuyzen, A.A., Dudbridge, F., & Middeldorp, C.M. Research Review: Polygenic methods and their application to psychiatric traits. *Journal of child psychology and psychiatry* 2014; **55**, 1068-1087 .
31. Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O'Donovan, M.C., Sullivan, P.F. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009; **460**, 748-752 .
32. Wray, N.R., Yang, J., Hayes, B.J., Price, A.L., Goddard, M.E., & Visscher, P.M. Pitfalls of predicting complex traits from SNPs. *Nature Reviews Genetics* 2013; **14**, 507-515 .
33. American Psychiatric Association Diagnostic and statistical manual of mental diseases. *DSM-IV. 4th edn. Washington (DC): American Psychiatric Association* 1994.
34. van Beijsterveldt, C.E., Groen-Blokhuis, M., Hottenga, J.J., Franic, S., Hudziak, J.J., Lamb, D. *et al.* The Young Netherlands Twin Register (YNTR): longitudinal twin and family studies in over 70,000 children. *Twin Research and Human Genetics* 2013; **16**, 252-267 .
35. Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J. *et al.* Cohort profile: the `children of the 90s` the index offspring of the Avon Longitudinal Study of Parents and Children. *International journal of epidemiology* 2012; dys064 .
36. Ebesutani, C., Bernstein, A., Nakamura, B.J., Chorpita, B.F., Higa-McMillan, C.K., Weisz, J.R. *et al.* Concurrent validity of the Child Behavior Checklist DSM-oriented scales: Correspondence with DSM diagnoses and comparison to syndrome scales. *Journal of Psychopathology and Behavioral Assessment* 2010; **32**, 373-384 .
37. Goodman, R., Ford, T., Richards, H., Gatward, R., & Meltzer, H. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. *Journal of child psychology and psychiatry* 2000; **41**, 645-655 .
38. Goodman, A., Heiervang, E., Collishaw, S., & Goodman, R. The 'DAWBA bands` as an ordered-categorical measure of child mental health: description and validation in British and Norwegian samples. *Social psychiatry and psychiatric epidemiology* 2011; **46**, 521-532 .

39. Vilhjalmsón, B., Yang, J., Finucane, H.K., Gusev, A., Lindström, S., Ripke, S. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *bioRxiv* 2015; 015859 .
40. Minicà, C.C., Dolan, C.V., Kampert, M.M., Boomsma, D.I., & Vink, J.M. Sandwich corrected standard errors in family-based genome-wide association studies. *European Journal of Human Genetics* 2014.
41. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software* 2010; **36**, 1-48 .
42. Higgins, J. & Thompson, S.G. Controlling the risk of spurious findings from meta-regression. *Statistics in medicine* 2004; **23**, 1663-1682 .
43. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet* 2013; **9**, e1003348 .
44. Pappa, I., Fedko, I.O., Mileva-Seitz, V.R., Hottenga, J.J., Bakermans-Kranenburg, M.J., Bartels, M. *et al.* Single nucleotide polymorphism heritability of behavior problems in childhood: Genome-wide complex trait analysis. *Journal of the American Academy of Child & Adolescent Psychiatry* 2015; **54**, 737-744 .
45. Trzaskowski, M., Eley, T.C., Davis, O.S., Doherty, S.J., Hanscombe, K.B., Meaburn, E.L. *et al.* First genome-wide association study on anxiety-related behaviours in childhood. *PLoS one* 2013; **8**, e58676 .
46. Golan, D., Lander, E.S., & Rosset, S. Measuring missing heritability: Inferring the contribution of common variants. *Proceedings of the National Academy of Sciences* 2014; **111**, E5272-E5281 .
47. Bellina, M., Brambilla, P., Garzitto, M., Negri, G.A., Molteni, M., & Nobile, M. The ability of CBCL DSM-oriented scales to predict DSM-IV diagnoses in a referred sample of children and adolescents. *European child & adolescent psychiatry* 2013; **22**, 235-246 .
48. Groen-Blokhuis, M.M., Middeldorp, C.M., Kan, K.J., Abdellaoui, A., van Beijsterveldt, C.E., Ehli, E.A. *et al.* Attention-deficit/hyperactivity disorder polygenic risk scores predict attention problems in a population-based sample of children. *Journal of the American Academy of Child & Adolescent Psychiatry* 2014; **53**, 1123-1129 .
49. Martin, J., Hamshere, M.L., Stergiakouli, E., OGÇÖDonovan, M.C., & Thapar, A. Genetic risk for attention-deficit/hyperactivity disorder contributes to neurodevelopmental traits in the general population. *Biological psychiatry* 2014; **76**, 664-671 .
50. Stergiakouli, E., Martin, J., Hamshere, M.L., Langley, K., Evans, D.M., St Pourcain, B. *et al.* Shared genetic influences between attention-deficit/hyperactivity disorder (ADHD) traits in children and clinical ADHD. *Journal of the American Academy of Child & Adolescent Psychiatry* 2015; **54**, 322-327 .
51. Martin, J., Tilling, K., Hubbard, L., Stergiakouli, E., Thapar, A., Smith, G.D. *et al.* Association of Genetic Risk for Schizophrenia With Nonparticipation Over Time in a Population-Based Cohort Study. *American Journal of Epidemiology* 2016; AOP .

52. Bulik-Sullivan,B., Finucane,H.K., Anttila,V., Gusev,A., Day,F.R., Consortium,R. *et al.* An Atlas of Genetic Correlations across Human Diseases and Traits. *bioRxiv* 2015.
53. Onstad,S., Skre,I., Torgersen,S., & Kringlen,E. Twin concordance for DSMGÇÉIIGÇÉR schizophrenia. *Acta Psychiatrica Scandinavica* 1991; **83**, 395-401 .
54. McGuffin,P., Farmer,A.E., Gottesman,I.I., Murray,R.M., & Reveley,A.M. Twin concordance for operationally defined schizophrenia: Confirmation of familiarity and heritability. *Archives of general psychiatry* 1984; **41**, 541-545 .




Figure 1: A forest plot of the observed associations between schizophrenia PRS (obtained at prior proportion of causal SNPs = 0.05) and of the model predicted associations. The blue polygons indicate the association as predicted from the meta-regression model, while the black square indicates the association as observed in the empirical data. The whiskers indicate the 95% confidence regions around the empirical PRS associations. The results are ordered by increasing age for each disorder, with in the top half the results in the ALSPAC cohort and in the bottom half the results for the NTR cohort.




Figure 2: Bubble plot showing the effect of age on the association between schizophrenia PRS and childhood psychopathology, split per disorder. Circles indicate the observed effect sizes in the univariate regression analyses (ALSPAC in blue, NTR in red). The size of the circles is proportional to the inverse of the variance, and thus larger circles reflect more accurate estimates. The solid line reflects the meta-regression fitted effect size and the dashed lines indicate the upper and lower 95% confidence interval around the meta-regression line.







Figure 3: Bubble plot of the approximated genetic correlations between schizophrenia and childhood psychopathology per disorder. We assume the variance in childhood psychopathology explained by all markers used to construct the PRS is 15% and constant over disorders and age. We further assume the PRS captures 200,000 independent genetic effects. Grades indicate the transformed observed regression coefficients to genetic correlations (ALSPAC in blue, NTR in red). The size of the circles is proportional to the inverse of the variance, and thus larger circles reflect more accurate estimates. The solid line reflects the genetic correlation and the dashed lines indicate the upper and lower 95% confidence interval around the genetic correlation, quantifying the uncertainty in the meta-regression but not in the variance in childhood psychopathology explained by all measured markers, or the estimate of the number of independent markers.



Supplementary Figure 1: Bubble plot of the relationship between the polygenicity prior and the effects size in the polygenic risk score analyses. Note the increase in effect size with the increase in polygenicity prior. The solid line indicates the best fit obtained from the meta-regression model (model 3) where the dashed lines reflect the upper and lower confidence bounds.



Supplementary Figure 2 Bubble plot of the approximated genetic correlations between schizophrenia and childhood psychopathology per disorder given the assumptions described in Supplementary Note 1. In this figure we assume the variance explained by all markers in childhood psychopathology is constant and 20%. Circles indicate the transformed observed regression coefficients to genetic correlations (ALSPAC in blue, NTR in red). The size of the circles is proportional to the inverse of the variance, and thus larger circles reflect more accurate estimates. The solid line reflects the genetic correlation and the dashed lines indicate the upper and lower 95% confidence interval around the genetic correlation, quantifying the uncertainty in the meta-regression but not in the variance in childhood psychopathology explained by all measured markers, or the estimate of the number of independent markers.



Supplementary Figure 3 Bubble plot of the approximated genetic correlations between schizophrenia and childhood psychopathology per disorder given the assumptions described in Supplementary Note 1. In this figure we assume the variance explained by all markers in childhood psychopathology is constant and 10%. Circles indicate the transformed observed regression coefficients to genetic correlations (ALSPAC in blue, NTR in red). The size of the circles is proportional to the inverse of the variance, and thus larger circles reflect more accurate estimates. The solid line reflects the genetic correlation and the dashed lines indicate the upper and lower 95% confidence interval around the genetic correlation, quantifying the uncertainty in the meta-regression but not in the variance in childhood psychopathology explained by all measured markers, or the estimate of the number of independent markers.

Table 1: Model fit comparison for the meta-regression models

	predictors	LL	df	LRT	p-val LRT	AIC	residual heterogeneity y (QE)	p-val QE	parametric resample
Model1	cohort	602.6325	2			-1200.476	274.2758	< 0.0001	0%
Model									
2	cohort age, prior, prior ² , disorder	616.8587	8	28.41	< 0.0001	-1216.885	245.867	0.0016	0.50%
Model									
3	cohort age, prior, prior ² , disorder, age x disorder	626.5272	11	19.37	0.0002	-1230.258	226.4939	0.0122	22.40%
Model									
4	cohort age, prior, prior ² , disorder, age x disorder, age ² x disorder	631.0907	15	9.046	0.06	-1231.304	217.448	0.0207	77.10%

This table contains the predictors, likelihood ratio test (LRT), AIC and residual heterogeneity for the 4 meta-regression models considered. The LRT tests the relative performance of adjacent models, model 2 is tested against model 1, model 3 is tested against model 2, and model 4 is tested against model 3. The test of residual heterogeneity considers whether the residual variance in the effects observed in the original studies, after conditioning on the predictors, still deviates from zero. Parametric resample reports on the percentage of resampled datasets in which each model fitted best according to the AIC.

Table 2: Parameter estimates and test statistics for meta-regression model 3

parameter	estimate	se	zval	pval	ci.lb	ci.ub
Intercept	0.0262	0.0115	2.2716	0.0231	0.0036	0.0487
age	0.0024	0.0008	2.9275	0.0034	0.0008	0.004
prior	0.0354	0.0155	2.284	0.0224	0.005	0.0657
prior ²	-0.0253	0.0109	-2.331	0.0198	0.0466	-0.004
cohort	-0.0221	0.0124	-1.7856	0.0742	0.0464	0.0022
anxiety	-0.0006	0.0016	-0.3771	0.7061	0.0039	0.0026
ODD/CD	-0.0042	0.0017	-2.4959	0.0126	0.0076	-0.0009
ADHD	-0.0027	0.0017	-1.6058	0.1083	-0.006	0.0006
age x anxiety	0.0003	0.0003	0.9681	0.333	0.0003	0.0008
age x ODD/CD	0.0006	0.0003	2.1763	0.0295	0.0001	0.0012
age x ADHD	0.001	0.0002	4.1855	<.0001	0.0005	0.0014

"Depression" serves as a reference disorder. Therefore the intercept and age effect reflect the expected association between schizophrenia and depression at age 7 and the yearly increase in the expected association. se: standard error, zval: z-value, pval: p-value, ci.lb: lower bound of 95% confidence interval, ci.ub: upper bound of 95% confidence interval

Supplementary Table 1: Sample sizes per age group for the NTR, ALSPAC and combined

Age	NTR	ALSPAC	Total
Age 7	2588	6127	8715
Age 10	2487	5934	8421
Age 12	2314	5496	7810
Age 15	1223	4445	5668

Supplementary Table 2: Descriptives

	NTR: mean and SD				ALSPAC: prevalence (%)	
	Female mean	SD	Male mean	SD	Female	Male
ODD/CD 7	-0.12	0.89	0.13	1.1	1.71%	5.42%
OOD/CD 10	-0.13	0.86	0.15	1.13	1.73%	4.51%
ODD/CD 12	-0.09	0.92	0.1	1.07	2.99%	3.95%
OOD/CD 15	0.01	0.96	-0.01	1.06	3.37%	4.02%
ADHD 7	-0.1	0.96	0.11	1.03	0.69%	3.12%
ADHD 10	-0.12	0.96	0.14	1.03	0.55%	2.43%
ADHD 12	-0.1	0.95	0.12	1.05	0.55%	2.01%
ADHD 15	0.06	1	-0.09	0.99	0.42%	1.25%
Depression 7	0.08	1.07	-0.09	0.9	0.44%	0.74%
Depression 10	0.03	1.05	-0.04	0.94	0.85%	0.85%
Depression 12	0.07	1.07	-0.08	0.9	0.71%	0.89%
Depression 15	0.14	1.08	-0.21	0.82	2.27%	0.98%
Anxiety 7	0.01	0.98	-0.01	1.03	1.34%	1.86%
Anxiety 10	0.02	0.99	-0.02	1.01	1.76%	1.95%
Anxiety 12	0.04	0.97	-0.05	1.03	1.17%	1.22%
Anxiety 15	0.23	1.03	-0.34	0.85	3.06%	0.77%

Note: For NTR: mean and standard deviation (SD) per age for the standardized scales for females and males. For ALSPAC: percentages of ALSPAC female and male participants affected with a psychiatric disorder as indicated by a score of 4 or 5 on the DAWBA band score

Supplementary Table 3: Prediction of non-participation based on the schizophrenian PRS

cohort	age	estimate	Z-stat	P-value
NTR	7	0.0639	0.68	0.49
	10	0.03	0.43	0.66
	12	-0.03	-0.78	0.43
	15	0.078	2.36	0.017
cohort	age	estimate	t-stat	P-value
ALSPAC	7	0.0858	3.77	< 0.001
	10	0.0864	3.86	< 0.001
	13	0.0861	3.97	< 0.001
	15	0.1192	5.6	< 0.0001

The polygenic risk score based on the polygenic prior set to 1 was used. Results did not vary strongly based on the prior.

Supplementary Table 4: Prediction of non-participation based on psychopathology scores at an earlier time point

cohort	Outcome	Predictor	estimate	Z-stat	P-value
NTR	missingness	ODD/CD			
	age 10	age 7	-0.021	-1.52	0.13
	age 12	age 10	-0.002	-0.09	0.93
	age 15	age 12	0.034	2.03	0.043
NTR	missingness	ADHD			
	age 10	age 7	-0.002	-0.46	0.65
	age 12	age 10	-0.002	-0.11	0.91
	age 15	age 12	0.012	1.05	0.29
NTR	missingness	Depression			
	age 10	age 7	-0.014	-1.77	0.077
	age 12	age 10	-0.02	-1.06	0.29
	age 15	age 12	0.041	2.61	0.009
NTR	missingness	Anxiety			
	age 10	age 7	-0.0089	-0.92	0.36
	age 12	age 10	-0.005	-0.5	0.62
	age 15	age 12	0.016	1.04	0.3
cohort	Outcome	Predictor	estimate	Z-stat	P-value
ALSPAC	missingness	ODD/CD			
	age 10	age 7	0.11	2.971	0.003
	age 13	age 10	0.28	7.23	< 0.001
	age 15	age 13	0.16	5.56	< 0.001
ALSPAC	missingness	ADHD			
	age 10	age 7	0.067	2.365	0.018
	age 13	age 10	0.193	6.876	< 0.001
	age 15	age 13	0.11	4.152	< 0.001
ALSPAC	missingness	Depression			
	age 10	age 7	0.026	0.637	0.0525
	age 13	age 10	0.093	2.55	0.011
	age 15	age 13	0.018	0.596	0.55
ALSPAC	missingness	Anxiety			
	age 10	age 7	-0.05331	-2.179	0.029
	age 13	age 10	0.025	1.01	0.312
	age 15	age 13	-0.011	-0.0518	0.604

The polygenic risk score based on the polygenic prior set to 1 was used. Results did not vary strongly based on the prior.

Supplementary Note 1

This note accompanies the manuscript entitled: “Genetic overlap between schizophrenia and developmental psychopathology: a longitudinal analysis of common childhood disorders between age 7 and 15”. All data described here and analyses presented here serve to support the conclusions of the manuscript as published.

Phenotypic descriptive statistics

Supplementary Table 2 presents the mean scores on the DSM-IV based scales of anxiety, depression, ADHD, ODD/CD for males and females in the NTR at different ages (left) as well as the percentages of male and female ALSPAC participants with these diagnoses, defined as a score of 4 or 5 on the DAWBA (right). (Note that in the analyses, the 6-category DAWBA band was used as outcome variable since this is a more informative measure than the dichotomous DAWBA diagnosis)

Genotyping and genotype quality control:

The NTR participants were genotyped on Affymetrix 6.0, Affymetrix-perlegen 5.0, Illumina 660 and Omni express (1M) platforms. Array specific calls and cleaning were performed before data from different platforms were combined. Data from different platforms were strand aligned, SNPs with a minor allele frequency below 1%, a HWE p-value $< 1 \times 10^{-5}$ and with a genotype missingness rate $> 10\%$ or call rate $< 95\%$ were removed. Individuals with an excessive or low heterozygosity were removed ($F > .10$ or $F < .10$). After QC, genotypes were imputed to a common set of SNPs based on the goNL reference set.¹ SNPs were imputed that were not directly measured on each platform. Samples were excluded when reported gender did not match biological gender or when individuals were of non-European ancestry based on principle component analysis.² In the NTR, sex, call rate, F (inbreeding coefficient), five principle components based on global ancestry and five principal components correcting for local ancestry differences within the Netherlands were included as covariates in all analyses.²

In ALSPAC, children were genotyped on the Illumina HumanHap550 quad chip genotyping platforms. The raw genome-wide data were subjected to standard quality control methods. Individuals were excluded on the basis of gender mismatches, minimal or excessive heterozygosity, disproportionate levels of individual missingness (>3%), and insufficient sample replication (IBD < 0.8). Population stratification was assessed by multidimensional scaling analysis, and compared with Hapmap II (release 22); all individuals of non-European ancestry were removed. SNPs with a minor allele frequency of < 1%, a call rate of < 95%, or evidence for violations of Hardy-Weinberg equilibrium ($p < 5E^{-7}$) were removed. Cryptic relatedness was measured as proportion of identity by descent (IBD > 0.1). Related subjects that passed all other quality control thresholds were retained during subsequent phasing and imputation. Imputation of the target data was performed using Impute V2.2.2³ against the 1000 genomes phase 1 version 3 reference panel, using all 2186 reference haplotypes (including non-Europeans)⁴. As the ALSPAC sample, after QC, is assumed to be genetically homogeneous with respect to ancestry and local ancestry differences, no principal components were added to as covariates, sex was included as covariate in all analyses.

The correction for the presence of overlapping subjects at the different ages of measurement, and the correlation between the polygenic predictors.

In the meta regression analysis performed we have a set of 6 predictors X, and 32 outcomes Y. We perform a series of 192 univariate regressions:

$$Y_1 = X_1 B_1 + e$$

...

$$Y_{32} = X_6 B_{192} + e$$

We construct an approximate error correlation matrix (i.e. the correlation between the regression parameters B) for a series of univariate regressions of p equal to:

$$\text{cor}(B) \approx (\text{cor}(Y)) \otimes (\text{cor}(X))$$

We specify the error *covariance* matrix as: $se * \text{cor}(B) * se$. Where se was a 192 x 192 diagonal matrix with the standard associated with each of the parameters B on the diagonal. The errors were assumed to be independent between cohorts and therefore correlations between cohorts were set to zero in matrix $\text{cor}(B)$. Based on the specified error correlation matrix, we performed the meta-analysis and meta-regression of the beta's obtained from the univariate regression analyses. To test the proposed error correlation matrix accurately accounts for the dependence induced by correlated predictors and outcomes, we performed type 1 error simulations.

We simulated 3 traits (Y) (correlations between .3 and .5) and 3 polygenic scores (X) (correlations between .9 and .8) for 100 subjects. In each simulation there is no true association between PRS and traits. We regress each trait Y on each polygenic score X , and meta analyze the 9 test statistics obtained from these regressions, correcting for the dependence between traits and risks cores as outlined above. Given a small sample in the univariate regressions ($N=100$) the following slightly liberal type 1 error rates were observed. The liberal type-1 error is likely induced by the fact that the test statistic obtained in each meta analysis follows a t-distribution and not a normal distribution.

Alpha	Type 1 error
0.10	0.123
0.05	0.065
0.01	0.015

Simulating data given a larger sample of 1000 subjects in the initial univariate regressions the following, accurate, type 1 error rates were observed:

Alpha	Type 1 error
0.10	0.102
0.05	0.052
0.01	0.01

In our study, the sample size for the individual univariate regressions to be meta-analyzed ranged between 1200 and 6000 thus we were satisfied with the results of the type-1 error simulations.

A different limitation was that the error covariance as specified here assumed total sample overlap, and the absence of any covariates. Note however we do include covariates to control for population stratification and mean differences between male and female participants and these effects are assumed to be sufficiently small to allow our approximation to be valid. Strong covariate effects and substantial dropout would likely reduce power to detect an overall or age effect, and possibly increase type 1 error in some situation. As a form of sensitivity analysis the off diagonal elements of the phenotypic correlation matrices in ALSPAC and NTR were shrunk by 50% or 33% and increased by up to 10% to simulate the effect of less than total sample overlap or the effect of covariates changing the error covariance matrix. The substantive conclusions remained virtually unchanged, model 3 as described in the main text, had the best model fit when the off-diagonal elements in the phenotypic covariance matrix were reduced 50 or 33%, model 4 performed best when the phenotypic covariance was increased 10%. Parameter estimates and test statistics in model 3, fitted on the increased or decreased error covariance matrix were virtually unchanged. The sensitivity analyses revealed the

effects of misspecification of the error covariance matrix did in all likelihood not influence the conclusions.

Parametric resampling of the data to account for the influence of sampling fluctuation

To quantify the influence of sampling fluctuation on our model selection we resampled the input for the meta-regression from a multivariate normal distribution with means equal to the observed regression coefficients in the univariate PRS analyses, and covariance equal to the above specified error covariance matrix. Unlike non-parametric bootstrapping this technique does make assumptions about the asymptotic distributions of test statistics. However parametric resampling does allow for quantification of sampling variance in the model selection procedure.

Mixed effects meta regression to account for residual heterogeneity

The best fitting fixed effects meta analysis model (model 3; **Table 1**) revealed a moderate amount of residual variation not accounted for by the meta regression model ($Q_e = 226,49$, $df=181$, $p = 0.0122$). We therefore performed 2 additional random effects meta analyses. Our First random effect model allowed for (correlated) random effects for each observed effect size, where the correlations between the random effect were assumed equal to the error covariance. The first mixed effects model significantly improves the model fit ($LRT=8.81$, $df = 1$, $p = 0.0009$). The fixed effects age, ODDCD, and agexADHD are all significant ($p < 0.05$) in this mixed effects model (as they were in the mixed effects meta-regression model) the effect agexODDCD no longer reaches significance ($p = 0.0681$). The omnibus test of all meta-regression parameters combined also remained significant

(QM = 37.0610, df = 10, p < 0.0001). The second mixed effects model includes a random intercept (i.e. In this model, the only dependence between effect sizes is introduced by the meta regressors or the error covariance. This second random effects model also significantly improves model fit over the fixed effects model (LRT = 14.7982, df=1, p < 0.0001). The second mixed effects model reveals a significant age effect and agexADHD effect (p < 0.05), but no significant ODDCD and agexODDCD effects. The overall test of moderators remains significant (QM= 30.0032, df=10, p = 0.0009. In general both mixed effects models retain the main conclusions of the fixed effects model (i.e an increasing association between schizophrenia PRS and childhood psychopathology with age, and some differences between the disorders in their relationship with schizophrenia).

Estimating genetic correlations based on polygenic risk score results

The univariate polygenic risk analyses results were obtained from either an ordered logistic regression (ALSPAC) or general estimation equations (GEE in NTR). For explanatory purpose we consider an OLS regression:

$$y = B_0 + B_1 * PRS + \dots + e$$

where the trait (y) and the PRS are scaled to unit variance and centered. The regression contains a number of other covariates (such as sex and principal components). Assuming the effects of the principal components and sex on the phenotypes are small to negligible, the square of B_1 (B_1^2) is equal to the variance explained in the phenotype by the PRS. We further assume that the squared predicted outcome of the multivariate meta-analyses correspond to R^2 . Given these assumptions we used the previously derived relationship between R^2 and genetic correlation⁵ to approximate the genetic correlations between childhood psychopathology and schizophrenia:

$$R^2 = \sigma_{g1,g2} \frac{\sigma_{g1,g2} * \frac{N}{M}}{\frac{N}{M} * \sigma_{g1}^2 + 1}$$

The inverse relationship equals:

$$\sigma_{g1,g2}^2 = R^2 / \frac{\frac{N}{M}}{\frac{N}{M} * \sigma_{g1}^2 + 1}$$

From which we can obtain:

$$r_g = \frac{\sigma_{g1,g2}^2}{\sqrt{\sigma_{g1}^2 * \sigma_{g2}^2}}$$

where N equals sample size in the discovery sample, M equals the independent number of genetic effects in the set of SNPs, $\sigma_{g1,g2}^2$ is the genetic covariance between target and discovery trait and σ_{g1}^2 equals the genetic variance explained by all measured markers in the target trait. As the discovery sample here is an ascertained case control sample (34241 cases and 45604 controls) we substitute the effective N using the effective sample size formula proposed by Wilier et al.⁶

$$N \approx \frac{4}{N_{cases}^{-1} + N_{controls}^{-1}}$$

Note that N is approximate and R^2 is estimated directly in the PRS analyses. Therefore, we needed to assume values for M and σ_{g1}^2 . Any uncertainty in these values will not be reflected in the confidence bounds around the genetic covariance. We assume M to equal 200.000, to explore the influence of the uncertainty in σ_{g1}^2 on the estimate of r_g we computed the genetic correlation assuming the heritability explained by all SNPs included in the score for childhood psychopathology is 0.15 (**Figure 3**), .20 (**Supplementary Figure 1**) or .10 (**Supplementary Figure 2**). Note that we do not

account for differences in the variance explained by the SNPs for the different psychopathologies at the different ages. We further assumed that the equations remain valid for estimates of B obtained from GEE (to correct for the presence of related samples) or ordered logistic regression (to correct for the fact that the ALSPAC phenotype was an ordered categorical variable).

Reference List

1. Genome of the Netherlands Consortium Whole-genome sequence variation, population structure and demographic history of the Dutch population. *Nature genetics* **46**, 818-825 (2014).
2. Abdellaoui, A. *et al.* Population structure, migration, and diversifying selection in the Netherlands. *European journal of human genetics* **21**, 1277-1285 (2013).
3. Howie, B.N., Donnelly, P., & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* **5**, e1000529 (2009).
4. Genomes Project Consortium An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56-65 (2012).
5. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet* **9**, e1003348 (2013).
6. Willer, C.J., Li, Y., & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).